Copertina

Letter: Resmetirom for treatment of MASH with children and adolescents

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yong‐Hai Zhou, Mohit Kehar, Nicholas Beng Hui Ng, Ming‐Hua Zheng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma?
di: Cuiyun Tao, et al.
Pubblicazione: (2025)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
di: Gong Feng, et al.
Pubblicazione: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
di: S. K. Bansal, et al.
Pubblicazione: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
di: Rui Zhang, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
di: Jing Li, et al.
Pubblicazione: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
di: WenXian OuYang, et al.
Pubblicazione: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
di: You‐Jian Xu, et al.
Pubblicazione: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
di: Leon A. Adams, et al.
Pubblicazione: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
di: Eric Lawitz, et al.
Pubblicazione: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
di: Rong‐Xiang Ng, et al.
Pubblicazione: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
di: Nikita Mittal, et al.
Pubblicazione: (2024)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
di: Matheus Souza, et al.
Pubblicazione: (2025)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
di: Mazen Noureddin, et al.
Pubblicazione: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
di: Veeral Ajmera, et al.
Pubblicazione: (2026)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
di: Matheus Souza, et al.
Pubblicazione: (2026)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
di: Maryam Alahmad, et al.
Pubblicazione: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
di: Senlin Ye, et al.
Pubblicazione: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics
di: George F. Longstreth
Pubblicazione: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
di: Kacie H. Denton, et al.
Pubblicazione: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
di: Mustafa Mohamedrashed, et al.
Pubblicazione: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
di: Richard Pollok
Pubblicazione: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
di: Fernanda Cristofori, et al.
Pubblicazione: (2025)